Medicure Launches Zypitamag Statin in the United States
May 15, 2018—Medicure Inc. recently announced that its Zypitamag (pitavastatin magnesium) tablets are now available in the United States, where they are sold through the company's subsidiary, Medicure Pharma, Inc. Zypitamag was approved as a statin (HMG-CoA reductase inhibitor) medication by the US Food and Drug Administration in July 2017. It is now available in strengths of 1, 2, and 4 mg.
Zypitamag is indicated for the treatment of patients with primary hyperlipidemia or mixed dyslipidemia as an adjunctive therapy to diet in order to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, triglycerides, as well as to increase high-density lipoprotein cholesterol.
Medicure has partnered with the drug's developer, Cadila Healthcare Ltd., India (Zydus group), to offer Zypitamag as a cost-effective pitavastatin alternative in the United States. Medicure entered into an agreement with Zydus to commercialize Zypitamag for a term of 7 years, with extensions to the term available. Zypitamag was developed by Zydus via a 505(b)(2) New Drug Application (NDA) procedure. Zydus will hold the NDA and Medicure will be responsible for the sales and marketing of Zypitamag.